CSIMarket
 


Sage Therapeutics Inc   (SAGE)
Other Ticker:  
 

Cumulative Sage Therapeutics Inc 's Quick Ratio for Trailing Twelve Months Period

SAGE's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

SAGE Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 26.43 % 8.48 % 8.99 % 16.51 % 26.28 %
Y / Y Cash & cash equivalent Growth -37.14 % -33.76 % -30.5 % -26.96 % -24.39 %
Quick Ratio for Trailing Twelve Months Period 10.52 12.61 14.24 15.87 17.84
Total Ranking # 204 # 174 # 163 # 160 # 156
Seq. Current Liabilities Growth 30.19 % 14.3 % -14.68 % -0.43 % 11.71 %
Seq. Cash & cash equivalent Growth -12.62 % -11.24 % -11.23 % -8.69 % -7.93 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to growth in Current Liabilities in the III. Quarter to $126 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 10.52 below Sage Therapeutics Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 153 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Sage Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about SAGE
Quick Ratio SAGE in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 154
Sector # 245
S&P 500 # 335


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
28.06 15.51 2.29
(Sep 30 2021)   (March 31, 2014)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Aprea Therapeutics Inc   28.93 
Dice Therapeutics Inc   28.90 
Design Therapeutics Inc   27.75 
Atossa Therapeutics Inc   27.49 
Imago Biosciences Inc   25.43 
Xenon Pharmaceuticals Inc   25.20 
Eliem Therapeutics Inc   25.01 
Theseus Pharmaceuticals Inc   24.50 
Terns Pharmaceuticals Inc   24.19 
Cyteir Therapeutics Inc   23.81 
Rezolute Inc   23.74 
Astria Therapeutics inc   23.71 
Eqrx Inc   23.58 
Briacell Therapeutics Corp   23.56 
Belite Bio Inc  22.70 
Disc Medicine Inc   21.84 
Gh Research Plc  21.73 
Diamedica Therapeutics Inc   20.70 
Savara Inc   20.61 
Prometheus Biosciences Inc   20.52 
Akero Therapeutics Inc   20.34 
Janux Therapeutics Inc   20.22 
Edgewise Therapeutics inc   20.11 
Kezar Life Sciences Inc   20.03 
Pmv Pharmaceuticals Inc   19.91 
Minerva Neurosciences Inc   19.82 
Kura Oncology Inc   19.60 
Nuvalent Inc   18.90 
Keros Therapeutics Inc   18.68 
Day One Biopharmaceuticals Inc   18.66 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com